Advertisement

PharmacoEconomics

, Volume 38, Issue 1, pp 1–4 | Cite as

The New and Non-Transparent Cancer Drugs Fund

  • Eifiona M. Wood
  • Dyfrig A. HughesEmail author
Commentary

Introduction

The Cancer Drugs Fund (CDF) in England was established in 2011 to facilitate access to cancer medicines that were not routinely available on the National Health Service (NHS). By 2015/2016, the cost of the CDF had reached £1.27 billion [1], and its value has been criticised extensively [2, 3, 4]. Since July 2016, a new arrangement that involves the National Institute for Health and Care Excellence (NICE) in the appraisal of CDF medicines has come into effect [5]. Medicines on the CDF as of 31 March 2016 were appraised by NICE and their continued funding was dependent on an expenditure control mechanism to prevent overspend, as had happened in previous years (e.g. by £126 million [37%] in 2015/2016). Under the current scheme, new cancer medicines may be recommended by NICE for routine commissioning (if considered to be clinically and cost effective), recommended for use within the new CDF (if there is good potential, but considerable clinical uncertainty), or not...

Notes

Author Contributions

EW and DH made substantial contributions to the conception and design of the work, and the acquisition, analysis, and interpretation of data; drafted the work and revised it critically for important intellectual content; approved the version to be published; and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Compliance with Ethical Standards

Conflicts of interest

Eifiona Wood and Dyfrig Hughes declare they have no conflicts of interest.

Funding

Dyfrig Hughes is a Senior Research Leader at Health and Care Research Wales.

References

  1. 1.
    House of Commons Committee of Public Accounts. Cancer Drugs Fund—20th Report. Twentieth Report of Session 2015–16. House of Commons; 2016.Google Scholar
  2. 2.
    Littlejohns P, Weale A, Kieslich K, et al. Challenges for the new Cancer Drugs Fund. Lancet Oncol. 2016;17(4):416–8.CrossRefGoogle Scholar
  3. 3.
    Graham J, Cassidy J, Hughes D, Duerden M. Ring-fencing a budget for cancer drugs: is it fair? J R Coll Physicians Edinb. 2011;41(3):224–8.CrossRefGoogle Scholar
  4. 4.
    Grieve R, Abrams K, Claxton K, et al. Cancer Drugs Fund requires further reform. BMJ. 2016;354:i5090.CrossRefGoogle Scholar
  5. 5.
    NHS England Cancer Drugs Fund Team. Appraisal and Funding of Cancer Drugs from July 2016 (including the New Cancer Drugs Fund). A New Deal for Patients, Taxpayers and Industry. NHS England Cancer Drugs Fund Team; 2016.Google Scholar
  6. 6.
    NHS England. National Cancer Drugs Fund List Version 1.72, 28 March 2018. NHS England; 2018.Google Scholar
  7. 7.
    National Institute for Health and Care Excellence. Consultation paper: value based assessment of health technologies. London: National Institute for Health and Care Excellence; 2014.Google Scholar
  8. 8.
    National Institute for Health and Care Excellence. Social value judgements: principles for the development of NICE guidance. 2nd ed. London: National Institute for Health and Care Excellence; 2008.Google Scholar
  9. 9.
    National Institute for Health and Care Excellence. Guide to the processes of technology appraisal 2018. National Institute for Health and Care Excellence; 2018. p. 1–104.Google Scholar
  10. 10.
    Bullement A, Taylor M, McMordie ST, Waters E, Hatswell AJ. NICE, in confidence: an assessment of redaction to obscure confidential information in single technology appraisals by the national institute for health and care excellence. Pharmacoeconomics. 2019;37(11):1383–90.CrossRefGoogle Scholar
  11. 11.
    Health Policy Watch. Medicine prices: secrecy of R&D costs remains issue in Near-Final World Health Assembly Resolution. Health Policy Watch; 2019. https://www.healthpolicy-watch.org/medicines-prices-secrecy-of-rd-costs-remains-issue-in-nearly-final-wha-resolution/. Accessed 2 June 2019.
  12. 12.
    NHS England. Cancer drugs fund (CDF) activity update Q4 2017–2018.Google Scholar
  13. 13.
    NHS Digital. Prescribing costs in hospitals and the community, England 2017/18. NHS; 2018.Google Scholar
  14. 14.
    National Institute for Health and Care Excellence. Pembrolizumab for treating PDL1- positive non-small-cell lung cancer after chemotherapy. technology appraisal guidance TA428 National Institute for Health and Care Excellence; 11 Jan 2017.Google Scholar
  15. 15.
    Morrell L, Wordsworth S, Schuh A, Middleton MR, Rees S, Barker RW. Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals. BMC Health Serv Res. 2018;18(1):393.CrossRefGoogle Scholar
  16. 16.
    National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. National Institute for Health and Care Excellence; 2013. pp. 1–93.Google Scholar
  17. 17.
    Department of Health and Social Care. 2018 Statutory scheme-branded medicines pricing impact assessment. 2018. http://qna.files.parliament.uk/qna-attachments/980149/original/2018_Statutory_Scheme_Impact_Assessment_1.pdf. Accessed 2 June 2019.
  18. 18.
    Collins M, Latimer N. NICE’s end of life decision making scheme: impact on population health. BMJ. 2013;346(7905):f1363.CrossRefGoogle Scholar
  19. 19.
    Department of Health and Social Care. The Handbook to the NHS Constitution for England. Department of Health and Social Care; 2019.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Centre for Health Economics and Medicines EvaluationBangor UniversityBangorUK

Personalised recommendations